Jessica Badger
Physician Assistant · Wilmington, DENPI 1740855444
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 160 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,699 and has fallen 54.3% since, to $776 in 2025. Among physician assistant clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$365
- AstraZeneca$354
- Bayer$342
- Merck$337
- Lilly USA, LLC$228
- Amgen$223
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,970100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 29 | $365 |
| AstraZeneca | 17 | $354 |
| Bayer | 18 | $342 |
| Merck | 15 | $337 |
| Lilly USA, LLC | 12 | $228 |
| Amgen | 12 | $223 |
| Novo Nordisk | 12 | $198 |
| Pfizer | 6 | $107 |
| Axsome Therapeutics, Inc. | 5 | $95 |
| Baxter Healthcare | 2 | $81 |
| Boehringer Ingelheim | 4 | $71 |
| Esperion Therapeutics, Inc. | 4 | $71 |
| AbbVie | 4 | $66 |
| Scpharmaceuticals Inc. | 2 | $63 |
| Johnson & Johnson | 3 | $50 |
| Angiodynamics, Inc. | 1 | $49 |
| Teva Pharmaceuticals USA, Inc. | 3 | $44 |
| Tactile Systems Technology Inc | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Boston Scientific | 1 | $34 |
| Heartflow, Inc. | 1 | $29 |
| Biotronik Inc. | 1 | $23 |
| Chiesi USA, Inc. | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Agepha Pharma FZ LLC | 1 | $14 |
| Medtronic | 1 | $13 |
How this compares
$2,970 in reported general payments places this provider in the 90th percentile of 527 physician assistant providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 52 | $81,350 |
| OzempicSemaglutide | 63 | $72,811 |
| FarxigaDapagliflozin Propanediol | 41 | $49,961 |
| XareltoRivaroxaban | 42 | $48,789 |
| EntrestoSacubitril/Valsartan | 22 | $35,810 |
| Repatha SureclickEvolocumab | 24 | $22,869 |
| EliquisApixaban | 16 | $20,586 |
| JardianceEmpagliflozin | 12 | $19,109 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $12,291 |
| Repatha SyringeEvolocumab | 16 | $8,997 |
| Rosuvastatin Calcium | 126 | $2,888 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 28 | $2,310 |
| Olmesartan Medoxomil | 71 | $1,633 |
| Carvedilol | 75 | $1,362 |
| Amiodarone Hcl | 37 | $1,357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $228 | $81,35052 claims |
| Novo NordiskOzempic | $198 | $72,81163 claims |
| AstraZenecaFarxiga | $354 | $49,96141 claims |
| Johnson & JohnsonXarelto | $50 | $48,78942 claims |
| NovartisEntresto | $365 | $35,81022 claims |
| PfizerEliquis | $107 | $20,58616 claims |
| Boehringer IngelheimJardiance | $71 | $19,10912 claims |
| Esperion Therapeutics, Inc.Nexlizet | $71 | $12,29113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 527 physician assistant providers in Delaware.
Other physician assistant in Wilmington
- Jason SaulWilmington$9K
- Brooke EnderleWilmington$7K
- Matthew StumpWilmington$5K
- Christopher HoverWilmington$5K
- Julie SimsWilmington$5K
- Joan TaddeiWilmington$4K
- Gabriel PelaezWilmington$4K
- Caitlin McCarryWilmington$4K
- Samantha DelfeldWilmington$4K
- Shannon MohollenWilmington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.